Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer

As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans. Because HIV Env is densely glycosylated with 75–90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design. Upon analysis of three HIV strains, we here find that site-specific glycosylation of Env from infectious virus closely matches Envs from corresponding recombinant membrane-bound trimers. However, viral Envs differ significantly from recombinant soluble, cleaved (SOSIP) Env trimers, strongly impacting antigenicity. These results provide a benchmark for virus Env glycosylation needed for the design of soluble Env trimers as part of an overall HIV vaccine strategy.HIV envelope (Env) is a potential vaccine antigen and its N-glycans are part of the epitope of broadly neutralizing antibodies. Here, the authors show that glycosylation of Env from infectious virus closely matches Env from recombinant membrane-bound trimers, while it differs significantly from recombinant soluble, cleaved Env trimers.

[1]  John P. Moore,et al.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.

[2]  M. Crispin,et al.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope , 2015, Journal of Virology.

[3]  E. Go,et al.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate , 2017, Biotechnology and bioengineering.

[4]  P. McKay,et al.  Discrete partitioning of HIV-1 Env forms revealed by viral capture , 2015, Retrovirology.

[5]  Torsten Schwede,et al.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..

[6]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[7]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[8]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[9]  M. Kirschner,et al.  The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. , 2006, Protein expression and purification.

[10]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[11]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[12]  Sung Kyu Park,et al.  A quantitative analysis software tool for mass spectrometry–based proteomics , 2008, Nature Methods.

[13]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.

[14]  D. Baker,et al.  Refinement of protein structures into low-resolution density maps using rosetta. , 2009, Journal of molecular biology.

[15]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[16]  Dennis R. Burton,et al.  Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16 , 2010, Journal of Virology.

[17]  Sreeurpa Ray,et al.  The Cell: A Molecular Approach , 1996 .

[18]  Young Do Kwon,et al.  Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.

[19]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[20]  H. Katinger,et al.  Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Burton,et al.  Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.

[22]  J. Yates,et al.  DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. , 2002, Journal of proteome research.

[23]  Weston B Struwe,et al.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.

[24]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[25]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[26]  D. Burton,et al.  Identification and specificity of broadly neutralizing antibodies against HIV , 2017, Immunological reviews.

[27]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[28]  E. Go,et al.  Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. , 2008, Journal of proteome research.

[29]  Ian A Wilson,et al.  Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. , 2015, Cell reports.

[30]  E. Go,et al.  Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers , 2017, Journal of Virology.

[31]  D. Burton,et al.  Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. , 2017, Immunity.

[32]  Andrew B. Ward,et al.  EMHP: an accurate automated hole masking algorithm for single-particle cryo-EM image processing , 2017, bioRxiv.

[33]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[34]  E. Lindahl,et al.  Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2 , 2016, bioRxiv.

[35]  Tongqing Zhou,et al.  Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.

[36]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[37]  John R Yates,et al.  Extracting Accurate Precursor Information for Tandem Mass Spectra by RawConverter. , 2015, Analytical chemistry.

[38]  David Hua,et al.  Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140 , 2015, Journal of Virology.

[39]  John P. Moore,et al.  CD4-induced activation in a soluble HIV-1 Env trimer. , 2014, Structure.

[40]  R. Desrosiers,et al.  Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding , 2016, Scientific Reports.

[41]  D. Burton,et al.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. , 2016, Immunity.

[42]  D. Burton,et al.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure , 2017, Immunity.

[43]  Nathaniel Echols,et al.  EMRinger: Side-chain-directed model and map validation for 3D Electron Cryomicroscopy , 2015, Nature Methods.

[44]  Y. Durocher,et al.  Therapeutic glycoprotein production in mammalian cells. , 2017, Journal of biotechnology.

[45]  D. Burton,et al.  Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies , 2013, Nature chemical biology.

[46]  A. Ward,et al.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer , 2016, Science.

[47]  James C Paulson,et al.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.

[48]  John P. Moore,et al.  Open and Closed Structures Reveal Allostery and Pliability in the HIV-1 Envelope Spike , 2017, Nature.

[49]  A. Helenius,et al.  Intracellular functions of N-linked glycans. , 2001, Science.

[50]  Dennis R Burton,et al.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.

[51]  Kai Zhang,et al.  Gctf: Real-time CTF determination and correction , 2015, bioRxiv.

[52]  D. Burton,et al.  The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade , 2011, PloS one.

[53]  R. Wyatt,et al.  Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties , 2015, PLoS pathogens.

[54]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[55]  Baoshan Zhang,et al.  Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 , 2013, Nature Structural &Molecular Biology.

[56]  J. Binley,et al.  HIV-1 Virus-Like Particles Bearing Pure Env Trimers Expose Neutralizing Epitopes but Occlude Nonneutralizing Epitopes , 2012, Journal of Virology.

[57]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[58]  J. Binley,et al.  Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected , 2011, Journal of Virology.

[59]  John R Yates,et al.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein , 2017, Nature Communications.

[60]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[61]  Erdmann Rapp,et al.  Quantitative mapping of glycoprotein micro-heterogeneity and macro-heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides. , 2013, Journal of mass spectrometry : JMS.

[62]  John P. Moore,et al.  A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.

[63]  J. Diedrich,et al.  Global site-specific analysis of glycoprotein N-glycan processing , 2018, Nature Protocols.

[64]  M. Crispin,et al.  Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1 , 2017, Expert review of proteomics.

[65]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[66]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[67]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[68]  A. Ward,et al.  Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. , 2015, Structure.

[69]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.